In accordance with article 5 of the Spanish Law RDL1/2015, the information set out in the following sections is intended for healthcare professionals.
Access to this information and all use which may be made thereof or of these contents is exclusive responsibility of those who use them. Noventure will not be held liable for any illegal or improper use or for the manipulation of the contents and information included in these pages.
Magazine
We are pleased to announce that we are expanding the international coverage of our products thanks to the recent signature of agreements with both new and loyal partners. These new partnerships further enable us to spread our global footprint.
Soon you will be able to find our products in the following territories:
Ukraine - Utipro® Plus (PHARM. FABRIK MONTAVIT GmbH)
Lebanon – Aprotecol®, Gelsectan® and Xilaplus® (SPEPHAL S.A.L.)
Romania and Greece – Gelsectan® (GALENICA, S.A.)
Israel - Gelsectan®, Aprotecol® and Tasectan® Duo (LAPIDOT MEDICAL).
South Africa - Aprotecol®, Utipro® Plus (CAMOX PHARMACEUTICALS Pty Ltd.)
Hungary – Tasectan® (ELVAPHARMA s.r.o.)
Extending our collaboration with these valuable partners helps us to fulfill the mission to bring our innovative solutions to patients around the world.
For further information about our products click here: http://noventure.com/products
Corporate Press Release: Noventure and Laboratorios Salvat enter into agreement to commercialise innovative medical device in Spain and Portugal for rhinitis and rhinosinusitis.
The agreement will see the global launch of Noventure’s novel nasal mucoprotection product.
We are pleased to announce the launch in France of UTIPRO® PLUS, our product for uncomplicated Urinary Tract Infections. The product is commercialized over the French territory under the umbrella brand Cysticare / Utipro plus and is distributed by Vemedia, our partner for the product in the Netherlands as well.
